• Publications
  • Influence
Telaprevir for previously untreated chronic hepatitis C virus infection.
Telaprevir with peginterferon-ribavirin was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in the majority of patients. Expand
Telaprevir for retreatment of HCV infection.
Telaprevir combined with peginterferon plus ribavirin significantly improved rates of sustained virologic response in patients with previously treated HCV infection, regardless of whether there was a lead-in phase. Expand
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
In this phase 2 study of patients infected with HCV genotype 1 who had not been treated previously, one of the three telaprevir groups had a significantly higher rate of sustained virologic response than that with standard therapy. Expand
Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998
The Working Party felt the need for a large study to redefine neuropsychiatric abnormalities in liver disease, which would allow the diagnosis of minimal (subclinical) encephalopathy to be made on firm statistical grounds, and suggested a modification of current nomenclature for clinical diagnosis of hepaticEncephalopathy. Expand
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
The AASLD/EASL Practice Guideline Subcommittee on Hepatic Encephalopathy are: Jayant A. Talwalkar (Chair, AASLD), Hari S. Conjeevaram, Michael Porayko, Raphael B. Merriman, Peter L.M. Jansen, andExpand
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
Therapy with sofosbuvir-ribavirin for 12 weeks in patients with hepatitis C virus genotype 2 infection and for 24 weeks in Patients with HCV genotype 3 infection resulted in high rates of sustained virologic response. Expand
ESPEN Guidelines on Enteral Nutrition: Liver disease.
EN by means of ONS is recommended for patients with chronic LD in whom undernutrition is very common and TF commenced early after liver transplantation can reduce complication rate and cost and is preferable to parenteral nutrition. Expand
Diagnosis and phenotypic classification of Wilson disease 1
The Wilson disease gene ATP7B encodes a P‐type ATPase, an inherited autosomal recessive disorder of hepatic copper metabolism leading to copper accumulation in hepatocytes and in extrahepatic organs such as the brain and the cornea. Expand
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Twelve weeks of treatment with ABT-450/r-ombitasvir and dasabuvir without ribavirin was associated with high rates of sustained virologic response among previously untreated patients with HCV genotype 1 infection. Expand
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.
Early, sustained suppression of HCV replication portends an SVR, and cessation of treatment may be contemplated in patients without a > or = 2 log10 reduction in HCV RNA after 12 weeks. Expand